Press Releases Latest Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays Press Releases Year None2022202120202019201820172016201520142013 Sep 01, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH) Aug 13, 2021 Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science Aug 04, 2021 Theratechnologies to Present at the Canaccord Genuity 41st Annual Growth Conference Jul 23, 2021 Theratechnologies Establishes New At-The-Market Facility Jul 15, 2021 Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH Jun 30, 2021 Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021 Jun 23, 2021 Theratechnologies Appoints New Board Member Jun 21, 2021 Theratechnologies Announces New Preclinical Findings for Its Lead Investigational Peptide-Drug Conjugate TH1902 for the Potential Treatment of Metastatic Cancers Jun 10, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss its SORT1+ Technology™ for the Treatment of All Sortilin-Expressing Cancers May 31, 2021 Theratechnologies Hires Vice President, Human Resources First page « Previous page ‹ Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 41 - 50 of 296
Oct 26, 2022 Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
Sep 01, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss Tesamorelin for the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Aug 13, 2021 Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science
Jul 15, 2021 Theratechnologies Reports Financial Results for the Second Quarter of Fiscal 2021 and Provides Update on Its Planned Phase 3 Clinical Trial in NASH
Jun 21, 2021 Theratechnologies Announces New Preclinical Findings for Its Lead Investigational Peptide-Drug Conjugate TH1902 for the Potential Treatment of Metastatic Cancers
Jun 10, 2021 Theratechnologies to Host Key Opinion Leader Event to Discuss its SORT1+ Technology™ for the Treatment of All Sortilin-Expressing Cancers
